Format
Sort by
Items per page

Send to

Choose Destination

Best matches for DABIGATRAN/TU:

Search results

Items: 1 to 20 of 1020

1.

[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].

Enríquez A, Baranchuk A, Corbalán R.

Rev Med Chil. 2019;147(1):73-82. doi: 10.4067/S0034-98872019000100073. Review. Spanish.

2.

Network meta-analysis: a new analysis tool of the experimental evidence.

De Vecchis R, Ariano C.

Minerva Med. 2019 Apr;110(2):173-175. doi: 10.23736/S0026-4806.18.05768-3. No abstract available.

PMID:
30821432
3.

Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.

Lee SR, Lee YS, Park JS, Cha MJ, Kim TH, Park J, Park JK, Lee JM, Kang KW, Shim J, Uhm JS, Kim J, Kim C, Kim JB, Park HW, Joung B, Choi EK.

Yonsei Med J. 2019 Mar;60(3):277-284. doi: 10.3349/ymj.2019.60.3.277.

4.

Statins and the risk of bleeding in patients taking dabigatran.

Ho BL, Lin YJ, Lin SF, Chou PS, Chen CF, Lin RT, Hu HH, Chao AC.

Acta Neurol Scand. 2019 May;139(5):455-461. doi: 10.1111/ane.13077. Epub 2019 Mar 4.

PMID:
30742307
5.

Atrial Fibrillation.

Young M.

Crit Care Nurs Clin North Am. 2019 Mar;31(1):77-90. doi: 10.1016/j.cnc.2018.11.005. Review.

PMID:
30736937
6.

Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study.

Molteni M, Crippa M, Orenti A, Polo Friz H, Menghini A, Tramacere P, Marano G, Cimminiello C, Boracchi P.

Clin Drug Investig. 2019 Apr;39(4):355-362. doi: 10.1007/s40261-018-0742-1.

7.

A link between cytotoxicity in cell culture and gastrointestinal side effects of oral anticoagulants: bench-to-bedside.

Kubat E, Gurpinar OA, Karasoy D, Onur MA.

Bratisl Lek Listy. 2018;119(11):706-712. doi: 10.4149/BLL_2018_126.

PMID:
30686004
8.

Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.

Wu S, Xie S, Xu Y, Que D, Yau TO, Wang L, Huang Y.

J Clin Nurs. 2019 May;28(9-10):1839-1846. doi: 10.1111/jocn.14797. Epub 2019 Feb 12.

PMID:
30667111
9.

Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment.

Kemaloğlu Öz T, Gürol T, Sarıgül NU, Aslan U, Kobegenova M, Aydın A, Soylu Ö, Dağdeviren B.

Turk Kardiyol Dern Ars. 2019 Jan;47(1):4-9. doi: 10.5543/tkda.2018.82830.

10.

Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion.

Comuth WJ, de Maat MPM, van de Kerkhof D, Malczynski J, Husted S, Kristensen SD, Münster AB.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):91-99. doi: 10.1093/ehjcvp/pvy047. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):99.

PMID:
30608563
11.

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.

De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI.

Thromb Haemost. 2019 Jan;119(1):14-38. doi: 10.1055/s-0038-1675816. Epub 2018 Dec 31. Review.

PMID:
30597497
12.

Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients.

Woo HG, Chung I, Gwak DS, Kim BK, Kang JH, Kim BJ, Bae HJ, Han MK.

J Clin Neurosci. 2019 Mar;61:160-165. doi: 10.1016/j.jocn.2018.10.102. Epub 2018 Dec 23.

PMID:
30587420
13.

Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.

Fang CW, Tsai YT, Chou PC, Chen HM, Lu CM, Tsao CR, Chen CL, Sun MC, Shih YS, Hsieh CY, Chen LA, Chen PL, Yeh JT, Li YH.

J Stroke Cerebrovasc Dis. 2019 Mar;28(3):815-820. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.029. Epub 2018 Dec 17.

PMID:
30573284
14.

Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report.

Sun H, Zhao Q, Wang Y, Lakin R, Liu X, Yu M, Yang H, Gao D, Chen W, Gao G, Yan M, He Y, Yang P.

Medicine (Baltimore). 2018 Dec;97(51):e13623. doi: 10.1097/MD.0000000000013623.

15.

[Efficacy of Idarucizmab in Patients with Intracranial Hemorrhage Preconditioned with Dabigatran].

Karibe H, Akamatsu Y, Narisawa A, Hayashi T, Kameyama M.

No Shinkei Geka. 2018 Dec;46(12):1117-1120. doi: 10.11477/mf.1436203878. Japanese. No abstract available.

PMID:
30572310
16.

Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?

Pretnar Oblak J, Sabovic M, Frol S.

J Stroke Cerebrovasc Dis. 2019 Mar;28(3):768-773. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.019. Epub 2018 Dec 6.

PMID:
30527792
17.

Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation.

Van Keer JM, Vanassche T, Droogne W, Rex S, Rega F, Van Cleemput J, Verhamme P.

Eur J Heart Fail. 2019 Jan;21(1):129-131. doi: 10.1002/ejhf.1356. Epub 2018 Dec 6. No abstract available.

PMID:
30520546
18.
19.

Så blev NOAK den dominerande behandlingen vid förmaksflimmer - Historiskt perspektiv på den kliniska utvecklingen.

Wallentin L.

Lakartidningen. 2018 Dec 4;115. pii: FAS7. Swedish. No abstract available.

20.

NOAK vid venös tromboembolism samt hantering av blödningar.

Själander S, Själander A.

Lakartidningen. 2018 Dec 4;115. pii: FAS3. Swedish. No abstract available.

Supplemental Content

Loading ...
Support Center